Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Idiopathic …,

… people in the U.S. Orphan Drug Designation qualifies a candidate for various development incentives, including tax credits for eligible clinical trials, …, … people in the U.S. Orphan Drug Designation qualifies a candidate for various development incentives, including tax credits for eligible clinical trials, …, Read More

Scroll to Top